These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28711176)

  • 1. Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease.
    Mehta J; Beukelman T
    J Pediatr; 2017 Oct; 189():31-39. PubMed ID: 28711176
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.
    Cabrera N; Lega JC; Kassai B; Wouters C; Kondi A; Cannizzaro E; Woerner A; Chausset A; Roethlisberger S; Jeanneret C; Aeschlimann F; Malik S; Duquesne A; Kaiser D; Higel L; Maes A; Berthet G; Hentgen V; Kone-Paut I; Belot A; Hofer M
    Joint Bone Spine; 2019 May; 86(3):343-350. PubMed ID: 30201476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.
    Rivière E; Sellam J; Pascaud J; Ravaud P; Gottenberg JE; Mariette X
    Arthritis Res Ther; 2018 Jun; 20(1):122. PubMed ID: 29884223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.
    Cabrera N; Avila-Pedretti G; Belot A; Larbre JP; Mainbourg S; Duquesne A; Janiaud P; Kassai B; Cucherat M; Lega JC
    Rheumatology (Oxford); 2020 Sep; 59(9):2226-2236. PubMed ID: 32449926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials.
    Amarilyo G; Tarp S; Foeldvari I; Cohen N; Pope TD; Woo JM; Christensen R; Furst DE
    Semin Arthritis Rheum; 2016 Dec; 46(3):312-318. PubMed ID: 27989499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
    Kearsley-Fleet L; Davies R; Baildam E; Beresford MW; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2016 Sep; 55(9):1556-65. PubMed ID: 26732349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer Therapies in Rheumatology.
    Bays A; Gardner GC
    Med Clin North Am; 2024 Sep; 108(5):829-842. PubMed ID: 39084836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologicals in Juvenile Idiopathic Arthritis.
    Saini I; Dawman L; Gupta N; Kabra SK
    Indian Pediatr; 2016 Mar; 53(3):260-1. PubMed ID: 27029697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.
    Taddio A; Cattalini M; Simonini G; Cimaz R
    Expert Rev Clin Immunol; 2016 Jun; 12(6):641-9. PubMed ID: 26809126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.